United States· US:0378-3266_a591eea6-af04-4207-b0f7-61fbada4719c

Etoposide

A etoposide product containing etoposide, registered in United States by Mylan Pharmaceuticals Inc.. The same ATC class is registered in 17 of our 19 countries.

ATC L01CB01US label

Checked against FDA National Drug Code directory (United States) on

Informational only — not a medical device.

SOURCE REGISTER · USFDA National Drug Code directory (Unite…normalisedEtoposideATCL01CB01REGISTER NO.US:0378-3266_a591eea6…PACKS LISTED2CHECKEDSeptember 27, 2026

Where it is registered

Etoposide is registered in 17 of 19 countries.

Countries holding a registration under ATC L01CB01 (etoposide), each read from that country’s own register.

  • This record: United States, from FDA National Drug Code directory (United States)
  • 10 of them publish a price we can compare per daily dose

Etoposide · ATC L01CB01

17 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of etoposide costs, country by country.

Normalised to the WHO defined daily dose (50 mg), the median price runs from $9.95 in France to $18.65 in Switzerland — a ×1.9 gap.

  • 2 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Etoposide · price per daily dose (50 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$18.65
  • FR France$9.95
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

FDA National Drug Code directory (United States)
Active substance
ETOPOSIDE
Manufacturer
Mylan Pharmaceuticals Inc.
Country
United States (US)
ATC code
L01CB01
ATC class
Etoposide
Defined daily dose
50 mg, O
Reimbursed
Not published by this register
Source register
FDA National Drug Code directory (United States)
Last checked
September 27, 2026

Packs & prices · 2

  • ndc11
    0378326694
    20 CAPSULE in 1 CARTON (0378-3266-94)
  • ndc11
    0378-3266-94

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

576 interactions on record for etoposide.

Graded by severity as the source publishes them — 30 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Etoposide · interactions on record

576 records

  • 30 severe
  • 290 moderate
  • 21 minor
  • 235 info

Most severe, free to view

  • CladribineL01BB04severe
  • AprepitantA04AD12moderate
  • RolapitantA04AD14moderate
  • EliglustatA16AX10moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Etoposide in 16 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All etoposide products

Authorised across Europe · EMA

The same active substance is authorised in 29 EEA countries. Names it is sold under:

  • Austria · Etoposid Accord, Etoposid Ebewe
  • Belgium · Celltop, Eposin
  • Bulgaria · Eтопозид Акорд
  • Cyprus · Etoposide Accord
  • Czechia · Etoposid Ebewe, Etoposide Accord
  • Germany · Eto-Cell, Eto-Cell®
  • Denmark · Etoposid Accord, Etoposid Ebewe
  • Estonia · Etoposide Accord, Etoposide Kabi
  • Spain · Etopósido Accord, Etopósido Hikma
  • Finland · Etoposid Fresenius Kabi, Etoposide Accord
  • France · Celltop, Etopophos
  • United Kingdom (Northern Ireland) · Etopophos, Etoposide
  • Greece · Etobion
  • Croatia · Etoposide Sandoz
  • Hungary · Etoposid Sandoz, Etoposide Accord
  • Ireland · Etoposide, Etoposide Accord Healthcare
  • Iceland · Etópósíð Accord
  • Italy · Etoposide Accord, Etoposide Hikma
  • Lithuania · Etoposid Ebewe, Etoposide Accord
  • Luxembourg · Eposin, Etoposide Accord Healthcare
  • Latvia · Etoposide Accord, Etoposide Ebewe
  • Netherlands · Eposin, Etoposide Accord
  • Norway · Etoposid Ebewe, Etoposid Fresenius Kabi
  • Poland · Etoposid Ebewe, Etopozyd Accord
  • Portugal · Etoposido Accord, Etoposido Hikma
  • Romania · Etoposid Accord, Etoposide Teva
  • Sweden · Eposin, Etopofos
  • Slovenia · Ebeposid, Eposin
  • Slovakia · Etoposid Sandoz, Etopozid Accord

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/174c5f82-7b79-47fa-84e6-c0dcbb225338
GET /v1/drugs/174c5f82-7b79-47fa-84e6-c0dcbb225338?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "route": "ORAL",
  "source": "ndc",
  "strength": "50",
  "substance": "ETOPOSIDE",
  "productndc": "0378-3266",
  "dosage_form": "CAPSULE",
  "dea_schedule": null,
  "strength_unit": "mg/1",
  "application_number": "ANDA075635",
  "marketing_category": "ANDA"
}

See everything about etoposide.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.